Renaissance Technologies
CRSP icon

Renaissance Technologies’s CRISPR Therapeutics CRSP Stock Holding History

Renaissance Technologies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,599
Closed -$382K – 3563
2024
Q1 		$382K Buy
+5,599
New +$401K ﹤0.01% 2979
2023
Q4 		– Sell
-143,067
Closed -$6.49M – 3794
2023
Q3 		$6.49M Sell
143,067
-144,733
-50% -$7.47M 0.01% 1160
2023
Q2 		$16.2M Sell
287,800
-207,303
-42% -$11.8M 0.02% 774
2023
Q1 		$22.4M Sell
495,103
-291,497
-37% -$14.2M 0.03% 658
2022
Q4 		$32M Buy
786,600
+193,300
+33% +$10.3M 0.04% 500
2022
Q3 		$38.8M Buy
593,300
+24,600
+4% +$1.78M 0.05% 399
2022
Q2 		$34.6M Sell
568,700
-133,600
-19% -$7.85M 0.04% 481
2022
Q1 		$44.1M Buy
702,300
+123,458
+21% +$7.75M 0.05% 388
2021
Q4 		$43.9M Buy
+578,842
New +$50.6M 0.05% 374
2021
Q2 		– Sell
-123,110
Closed -$15M – 3501
2021
Q1 		$15M Sell
123,110
-30,090
-20% -$4.54M 0.02% 944
2020
Q4 		$23.5M Sell
153,200
-241,500
-61% -$28.5M 0.03% 677
2020
Q3 		$33M Buy
394,700
+26,042
+7% +$2.31M 0.03% 520
2020
Q2 		$27.1M Sell
368,658
-140,517
-28% -$8.22M 0.02% 661
2020
Q1 		$21.6M Buy
509,175
+114,611
+29% +$5.92M 0.02% 728
2019
Q4 		$24M Buy
394,564
+355,264
+904% +$19.4M 0.02% 911
2019
Q3 		$1.61M Buy
+39,300
New +$1.88M ﹤0.01% 2387
2019
Q1 		– Sell
-11,400
Closed -$326K – 3478
2018
Q4 		$326K Buy
+11,400
New +$396K ﹤0.01% 2999
2018
Q3 		– Sell
-171,100
Closed -$10.1M – 3370
2018
Q2 		$10.1M Buy
+171,100
New +$9.75M 0.01% 1346

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies's CRSP Position: Q2 2024 in Review

Renaissance Technologies sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 5,599 shares — an estimated $382K sold.

Renaissance Technologies first reported a position in CRSP in Q2 2018 and held it in 18 quarters. The position peaked at $44.1M in Q1 2022. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Renaissance Technologies reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Renaissance Technologies sold 5,599 CRISPR Therapeutics shares in Q2 2024, an estimated $382K.
  • Renaissance Technologies first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 18 quarters.
  • Renaissance Technologies's CRISPR Therapeutics position peaked at $44.1M in Q1 2022.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.